NRX Pharmaceuticals (NRXP) Net Cash Flow (QoQ) (2018 - 2026)
NRX Pharmaceuticals (NRXP) Net Cash Flow (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NRX Pharmaceuticals | 137.57 Mn | 130.87 Mn | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -274.24% |
| Dec 31, 2025 | -90.86% |
| Sep 30, 2025 | 359.10% |
| Jun 30, 2025 | -164.26% |
| Mar 31, 2025 | 2,122.17% |
| Dec 31, 2024 | 19.44% |
| Sep 30, 2024 | -143.52% |
| Jun 30, 2024 | 117.67% |
| Mar 31, 2024 | 23.94% |
| Dec 31, 2023 | 29.01% |
| Sep 30, 2023 | -294.73% |
| Jun 30, 2023 | 56.68% |
| Mar 31, 2023 | -296.57% |
| Dec 31, 2022 | 128.66% |
| Sep 30, 2022 | 59.76% |
| Jun 30, 2022 | -224.27% |
| Mar 31, 2022 | 211.69% |
| Dec 31, 2021 | -144.23% |
| Sep 30, 2021 | 22,072.17% |
| Jun 30, 2021 | -98.99% |